rethinkPeptides Search
Menu
Study breakdown

A New High-Throughput Method for Measuring Neuropeptide Release from Brain Cells

evidence
The takeaway

Researchers developed a sensitive, scalable assay using a neuropeptide Y-Nanoluc reporter that accurately measures neuropeptide secretion from both mouse and human neurons.

100+ neuropeptides

Over 100 neuropeptides modulate brain functions, but studying their release has been limited to slow, single-cell methods — this assay changes that

What the researchers found

The NPY-Nanoluc chimera accurately colocalized with endogenous dense core vesicle (DCV) markers in neurons, with minimal mislocalization to other cellular compartments. The reporter successfully detected DCV exocytosis in both rodent neurons and human neurons derived from induced pluripotent stem cells.

The assay showed the same calcium, RAB3, and STXBP1/MUNC18 dependence as established low-throughput methods, confirming its biological accuracy. It correctly reported modulation by known pharmacological agents (diacylglycerol analog and calcium channel blocker) and demonstrated higher sensitivity than the widely used single-cell low-throughput assay.

Why it matters

With over 100 neuropeptides in the brain linked to conditions from depression to epilepsy, researchers need faster ways to study how these signals are released. Current methods are slow and can only measure one cell at a time. This high-throughput assay could dramatically accelerate drug screening for neurological disorders by enabling large-scale testing of compounds that modulate neuropeptide secretion.

How the study worked

Researchers engineered a chimeric protein by fusing neuropeptide Y (NPY) to Nanoluc luciferase. This reporter was expressed in mouse neurons and human induced pluripotent stem cell-derived neurons. They validated its localization to dense core vesicles using colocalization with endogenous DCV markers, then tested its ability to report exocytosis under various conditions including depolarization, calcium manipulation, and pharmacological modulation. Performance was compared against established single-cell low-throughput assays.

What this study cannot tell us

The assay measures bulk neuropeptide release from neuronal populations rather than single-cell dynamics. The reporter uses an exogenous NPY-Nanoluc construct, which may not perfectly replicate the behavior of all endogenous neuropeptides. Validation was performed in vitro, so in vivo applicability remains to be demonstrated. The induced pluripotent stem cell-derived human neurons may not capture the full diversity of neuronal subtypes.

How to read the evidence

This is a methods development study that validates a new research tool. While it demonstrates strong technical performance and biological accuracy compared to established assays, it is not a therapeutic study and does not test clinical outcomes.

When this study was published

Published in 2024, this tool is very recent and represents the current frontier of neuropeptide research methodology. Its adoption could shape drug discovery pipelines in the near future.

The bigger picture

Neuropeptide dysregulation is implicated in a wide range of CNS disorders, but therapeutic development has been hampered by the difficulty of studying neuropeptide release at scale. This assay removes a key bottleneck. By enabling high-throughput pharmacological and genomic screening in human neurons, it opens the door to discovering new drug targets and understanding the genetic basis of neuropeptide secretion disorders.

Questions still open

  • Can this assay be adapted to measure the release of specific neuropeptides other than NPY?
  • How will this tool perform in large-scale drug screening campaigns for CNS disorders?
  • Could this approach be extended to measure neuropeptide secretion in brain organoids or in vivo models?

Common questions

What problem does this new assay solve for neuropeptide research?
Previous methods for measuring neuropeptide release from neurons were slow and could only analyze one cell at a time. This new NPY-Nanoluc assay allows researchers to measure neuropeptide secretion from many neurons simultaneously, dramatically speeding up experiments and drug screening.
Does this assay work with human neurons?
Yes. The researchers validated the NPY-Nanoluc reporter in both mouse neurons and human neurons derived from induced pluripotent stem cells, showing it works reliably across species — a key requirement for translational drug discovery.

Read the original research

High-throughput assay for regulated secretion of neuropeptides in mouse and human neurons.

The Journal of biological chemistry, 300(6), 107321

Citation

Baginska, Urszula; Balagura, Ganna; Toonen, Ruud F; Verhage, Matthijs. (2024). High-throughput assay for regulated secretion of neuropeptides in mouse and human neurons.. The Journal of biological chemistry, 300(6), 107321. https://doi.org/10.1016/j.jbc.2024.107321